Iovance Biotherapeutics was the first drug developer to win FDA approval of an immune cell/T-cell therapy.
The underlying science, however, may offer more long-term potential than the single drug in question.
This stock’s tremendous upside potential is paired with the possibility of turning into a complete bust.
10 stocks we like better than Iovance Biotherapeutics ›
Most investors don’t truly expect a single, relatively small trade to explode into a seven-figure holding. On the other hand, the prospect can’t be entirely ruled out either. It’s certainly been done before by the right company in the right place at the right time with the right product.
Enter Iovance Biotherapeutics (NASDAQ: IOVA). The up-and-coming biopharma outfit’s science is turning a lot of heads these days, and for good reason. But does it actually have millionaire-making potential?
Image source: Getty Images.
Biopharmaceuticals can be a tricky industry for investors to navigate. These companies’ scientific premises don’t always pan out as hoped, and even when they do, marketability of that new drug isn’t always guaranteed. Factors like pricing, competition, and safety always come into play as well.
Still, there’s nothing wrong with looking at a drug developer’s risk and potential reward.
With that as the backdrop, know that Iovance Biotherapeutics brings plenty of both to the table, even if the market is pricing in too much of one and not enough of the other.
In simplest terms, Iovance has successfully created a new way of treating unresectable or metastatic tumors. Its tumor-infiltrating lymphocyte (TIL) called Amtagvi (or Lifileucel), in fact, is the world’s first approved tumor-infiltrating lymphocyte, as well as the first immune cell/T-cell therapy approved to treat any solid tumors, winning the FDA’s approval early last year thanks to its 61% response rate for patients who had already tried two or fewer treatment options.
Although Amtagvi’s only approved for one specific purpose now, know that the company’s got 12 other trials of the…
..
